Other sources include CSF, spinal fluids, urine, and pleural effusion.Д®asy availability of biological specimens, such as urine, is likely to accelerate adoption under this segment. Low use of bone marrow-derived cells in clinical settings has contributed to a smaller revenue share of this segment. This has resulted in a segment's large revenue share.Д¬urrently, whole blood specimens are the key source of CTCs, thus accounting for the largest share in 2020. The presence of high-throughput automated systems coupled with the availability of a substantial number of systems to carry out detection of tumor cells has contributed to a large revenue share.Д¬TC analysis has major applications in research settings, including investigational research, drug developments, and biomarker studies. The devices and systems segment dominated the market in terms of revenue share in 2020 over its counterpart segments including kits and reagents and blood collection tubes. The growing application of nanomaterials in cancer management is anticipated to drive revenue for direct detection methods in the coming years. Moreover, high penetration in terms of usage of products offered under this segment has driven the segment share. The CTC detection and enrichment methods accounted for the largest revenue share owing to the presence of wide availability of products for CTC enrichment and isolation. For instance, there is negligible evidence for the characterization of CTCs for sarcoma.Д¬onversely, several methods are being investigated for the isolation of these cells, such as methods based on epithelial antigen-targeted antibodies, which are anticipated to help overcome these challenges in the coming years.Д¬irculating Tumor Cells Market Report Highlights The limited applicability of these cells in rare cancers has hampered the revenue growth up to a certain extent. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area.

Linearx systems inc